diabetic macular oedema

News

Bispecific antibody firm Ollin raises $330m in bumper round

Ollin has followed its $100m Series A last year with a massive $330m second round that will fund phase 3 trials of its challenger to Roche's Vabysmo.

News

Boehringer raises hope of oral drug for diabetic eye disease

Boehringer has started a phase 2 trial of an oral therapy that could help people with diabetic macular oedema avoid regular injections into the eye.

News

After FDA says no, Bayer bags EU nod for twice-yearly Eylea

Bayer has been given a leg up in the competitive market for VEGF therapies used to treat eye diseases with a new EU approval for Eylea 8mg.

News

Graphic representation of an implant into an eyeball

FDA expands label for Roche's eye disease implant Susvimo

The renaissance of Roche's refillable ophthalmic implant Susvimo has continued with FDA approval for use in patients with diabetic macular oedema.

News

Regeneron builds in eye disease tech with Oxular takeover

Regeneron has bought Oxular, a UK specialist in retinal diseases, in a move that bolsters its already strong position in ophthalmology therapies.

News

Roche trial confirms Vabysmo efficacy in minorities

A study has shown that Roche's diabetic macular oedema (DME) therapy Vabysmo is effective in patients who identify as African American, Black, Hispanic and Latino, plugging a gap in the dat

Bispecific antibody firm Ollin raises $330m in bumper round

Boehringer raises hope of oral drug for diabetic eye disease

After FDA says no, Bayer bags EU nod for twice-yearly Eylea

FDA expands label for Roche's eye disease implant Susvimo

Regeneron builds in eye disease tech with Oxular takeover

Roche trial confirms Vabysmo efficacy in minorities

ASCO 2026: Can a blood test spot cancer early? with Dr Peter...

Discover a new era of healthcare panel engagement: Grounded ...

diabetic macular oedema

Editor's Picks